{"filings":[{"id":869722,"accession_number":"0001104659-26-070636","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2026-06-04T23:21:48+00:00","items":["5.07"],"status":"ready","headline":"Scholar Rock annual meeting elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Hallal, Kristina Burow, Michael Gilman, and Katie Peng elected as Class II directors with 86.7M-96.3M votes for each.","Ratification of Deloitte & Touche as auditor for FY 2026: 113.4M for, 764.5K against, 500.0K abstain.","Non-binding advisory vote on named executive officer compensation: 68.3M for, 42.5M against, 131.0K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95036,"accession_number":"0001104659-26-056655","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock reports Q1 net loss $105.5M; FDA accepts apitegromab BLA with Sep 30 PDUFA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted apitegromab BLA for SMA; PDUFA action date Sep 30, 2026; two fill-finish facilities included.","Cash of $479.9M as of Mar 31, 2026, includes $100M debt draw and $98M ATM proceeds.","Q1 2026 net loss $105.5M ($0.83 per share) vs $74.7M ($0.67) in Q1 2025; no revenue.","R&D expense $51.8M, G&A $50.2M; stock-based compensation $18.2M.","Pipeline: Phase 2 OPAL trial enrolling; FORGE FSHD trial on track for mid-2026; SRK-439 Phase 1 data H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107815,"accession_number":"0001104659-26-037350","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Scholar Rock resubmits BLA for apitegromab SMA; PDUFA goal late Sept 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmission follows Sep 2025 CRL related to Catalent Indiana facility; no other approvability concerns cited.","FDA acceptance expected within 30 days; review up to 6 months; PDUFA decision target late September 2026.","Includes second U.S. fill-finish facility after positive Type C meeting on March 3, 2026.","European MAA for apitegromab progressing; decision anticipated mid-2026.","CEO David L. Hallal expects U.S. and European approvals and launches this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107814,"accession_number":"0001104659-26-022547","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock reports FY2025 net loss $378M; BLA resubmission expected in 2026 after FDA reinspection","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $377.9M for 2025 ($3.29 per share) vs $246.3M in 2024; no revenue; cash $367.6M at Dec 31.","Apitegromab BLA resubmission planned for 2026 after successful FDA reinspection of Catalent Indiana facility.","Secured up to $550M non-dilutive debt facility with Blue Owl Capital; $100M drawn to retire prior debt.","EMA decision on apitegromab MAA expected mid-2026; European launch (starting Germany) in H2 2026.","Phase 2 FORGE trial for FSHD on track for mid-2026; SRK-439 Phase 1 topline data expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107812,"accession_number":"0001104659-26-022897","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K/A","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock widens FY2025 net loss to $377.9M; corrects Q4 EPS to $0.76; BLA resubmission path cleared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss of $91.0M ($0.76 per share, corrected); FY2025 net loss $377.9M ($3.29 per share), up from $246.3M in 2024.","No revenue; cash, equivalents, and marketable securities of $367.6M as of Dec 31, 2025.","Apitegromab BLA resubmission expected in 2026 after FDA constructive meeting with Catalent Indiana; no additional corrective actions.","New debt facility up to $550M from Blue Owl Capital provides non-dilutive capital; $100M drawn at closing, $100M available Q1 2026, $150M upon FDA approval.","EMA decision on MAA expected mid-2026; European launch planned H2 2026 starting with Germany."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107813,"accession_number":"0001104659-26-002757","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Scholar Rock provides 2026 priorities; ~$365M cash; apitegromab BLA resubmission expected in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash of ~$365M as of Dec 31, 2025; expected runway into 2027.","Apitegromab BLA resubmission for SMA anticipated in 2026; U.S. launch expected after FDA approval.","IND cleared for FSHD; Phase 2 FORGE trial initiation and dosing expected mid-2026.","Subcutaneous apitegromab Phase 1 completed; SRK-439 Phase 1 topline data expected H2 2026.","EMA MAA decision for apitegromab expected mid-2026; second U.S. fill-finish facility capacity reserved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124214,"accession_number":"0001104659-25-117522","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Scholar Rock manufacturing partner Catalent Indiana receives FDA Warning Letter; 2026 apitegromab launch still expected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Catalent Indiana (Novo Nordisk) received FDA Warning Letter for facility with 'official action indicated' classification.","Scholar Rock reiterates expectation to resubmit BLA for apitegromab in SMA and achieve U.S. launch in 2026.","Company continues to collaborate with Catalent to resolve FDA issues; no change to prior timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124213,"accession_number":"0001104659-25-111956","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Scholar Rock expands ATM equity offering by up to $200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to sell up to $200,000,000 of common stock via ATM program through Jefferies LLC.","Shares offered under existing shelf registration statement (Form S-3ASR, File No. 333-282530).","Original ATM program dated November 14, 2022; new prospectus supplement filed November 14, 2025.","Legal opinion from Goodwin Procter LLP attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124212,"accession_number":"0001104659-25-111931","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock Q3 net loss $102.2M; Type A FDA meeting positive for apitegromab BLA resubmission in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $102.2M (EPS -$0.90) vs $64.5M (EPS -$0.66) YoY; no revenue.","Cash $369.6M; plus ~$60M from warrants expiring Dec 31, 2025, expected to fund into 2027.","Type A meeting with FDA completed Nov 12; BLA resubmission and U.S. launch for apitegromab in SMA anticipated in 2026.","Second U.S. fill-finish facility secured; commercial capacity reserved starting Q1 2026.","FDA cleared IND for SRK-439; dosing in healthy volunteers to begin Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124211,"accession_number":"0001104659-25-098894","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Scholar Rock notified that FDA classifies Catalent Indiana facility as 'official action indicated'","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Novo Nordisk informed Scholar Rock on Oct 10 that FDA classified Catalent Indiana (owned by Novo Nordisk) as 'official action indicated' (OAI).","OAI classification follows a Form FDA 483 issued July 14, 2025, citing significant objectionable conditions at the facility.","Filing does not specify the impact on Scholar Rock's manufacturing, supply chain, or regulatory timelines.","Scholar Rock provided no assessment of potential delays or financial effect in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140878,"accession_number":"0001104659-25-092317","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA issues CRL for Scholar Rock's apitegromab BLA due to Catalent fill-finish observations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL cites observations at Catalent Indiana fill-finish facility; no efficacy/safety issues.","Scholar Rock intends to resubmit BLA upon resolution of Catalent remediation.","Catalent submitted comprehensive response in August 2025; FDA kept apprised of progress.","EU MAA under review; decision expected mid-2026; launch anticipated H2 2026 in Germany first."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140877,"accession_number":"0001558370-25-010399","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock Q2 loss $110M; apitegromab PDUFA Sept 22, 2025; positive EMBRAZE lean mass data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted apitegromab BLA under priority review; PDUFA target action date September 22, 2025.","Phase 2 EMBRAZE trial: apitegromab + tirzepatide preserved 54.9% more lean mass vs tirzepatide alone (p=0.001).","Q2 net loss $110M ($0.98/shr) vs $58.5M ($0.60/shr) in prior year; no revenue.","Cash $295M as of June 30, 2025; expected to fund operations into 2027.","Preparing for U.S. commercial launch upon potential approval; EMA MAA validated, EU launch anticipated 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158632,"accession_number":"0001558370-25-008711","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Scholar Rock Phase 2 EMBRAZE trial shows 54.9% lean mass preservation with apitegromab plus tirzepatide (p=0.001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: apitegromab + tirzepatide preserved 54.9% of lean mass (p=0.001) vs tirzepatide alone over 24 weeks.","Patients on combination lost 18.8 lbs fat mass vs 17.7 lbs for tirzepatide alone; total weight loss 12.3% vs 13.4%.","Quality of weight loss improved: 85% fat / 15% lean mass loss with combination vs 70% fat / 30% lean with tirzepatide alone.","Apitegromab well tolerated; no SAEs or discontinuations related to apitegromab, consistent with prior studies.","Company plans to file IND for next-gen SRK-439 in H2 2025; conference call today at 8 AM EDT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158631,"accession_number":"0001558370-25-008364","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Scholar Rock appoints Deloitte & Touche as new independent auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee appointed Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.","Appointment follows a competitive process; no prior consultations with Deloitte on accounting principles or audit opinions.","No disagreements (per Item 304) or reportable events occurred during the past two fiscal years or interim period through June 3, 2025.","Change effective June 3, 2025; prior auditor not dismissed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158630,"accession_number":"0001558370-25-008134","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Scholar Rock reports annual meeting results; Backstrom resigns as CEO, auditor ratification withdrawn","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Srinivas Akkaraju and Joshua Reed elected to three-year Class I terms.","Non-binding say-on-pay approved: 84,838,269 votes for, 3,279,486 against.","Proposal to ratify Ernst & Young as independent auditor was withdrawn.","Jay T. Backstrom previously resigned as CEO/President and from the Board on April 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158629,"accession_number":"0001558370-25-007650","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock Q1 net loss $74.7M; BLA priority review set for Sept 22, 2025; cash to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $74.7M ($0.67 per share) vs $56.9M in Q1 2024; no revenue.","Cash, equivalents, securities $364.4M as of March 31, 2025; expected to fund into 2027.","FDA accepted BLA for apitegromab with priority review; PDUFA date Sept 22, 2025.","Topline results from Phase 2 EMBRAZE obesity trial expected June 2025.","Leadership: David Hallal CEO; Akshay Vaishnaw President R&D; Keith Woods COO; Vikas Sinha CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158628,"accession_number":"0001104659-25-047324","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Scholar Rock auditor EY declines re-election; no disagreements reported","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ernst & Young notified Scholar Rock on May 6, 2025 it will not stand for re-election as auditor for FY2025.","EY's service will end after the Q1 2025 Form 10-Q is filed.","No disagreements or reportable events occurred during FY2024, FY2023, or the interim through May 6, 2025.","Company and Audit Committee have begun discussions with other firms to engage a new independent auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158627,"accession_number":"0001104659-25-039854","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock appoints David Hallal as CEO; adds new President of R&D, COO, and CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Hallal (formerly Chairman) becomes CEO effective April 27, 2025; Jay Backstrom transitions to Senior Advisor through Oct 31.","Akshay Vaishnaw named President of R&D; Keith Woods as COO; Vikas Sinha as CFO; all start April 27.","Hallal receives $975k base salary, $2M sign-on bonus, $7.5M option grant, and 250k RSUs plus performance-based PSUs.","Dr. Backstrom will not stand for re-election at May 22 annual meeting; Board reduced from 10 to 9 members.","Company notes BLA for apitegromab accepted under priority review; leadership transition ahead of anticipated launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177028,"accession_number":"0001558370-25-003477","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["5.02","5.08"],"status":"ready","headline":"Scholar Rock appoints Erin Moore as interim CFO and PAO; annual meeting set for May 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Moore (SVP, Finance) appointed interim Principal Financial Officer and Principal Accounting Officer, effective March 21, 2025.","Moore, age 50, joined in 2018 as VP Finance and Controller; previously served as interim PAO from Oct 2019 to Jul 2020.","Appointment follows the previously announced departure of former COO & CFO Edward Myles on March 15, 2025.","2025 Annual Meeting of Stockholders to be held virtually on May 22, 2025; record date March 26, 2025.","Deadline for stockholder proposals and director nominations for proxy statement is March 31, 2025 at 5:00 p.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177027,"accession_number":"0001558370-25-001681","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock reports FY 2024 net loss of $2.47/share; BLA submitted for apitegromab in SMA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $246.3M ( $2.47 /share) vs $165.8M ( $1.99 /share) in FY 2023; zero revenue.","Cash, equivalents & marketable securities $437.3M; expanded credit facility adds up to $150M in tranches.","BLA for apitegromab in SMA submitted Jan 2025; US launch planned 4Q 2025; EU MAA expected 1Q 2025.","Phase 2 EMBRAZE topline data (apitegromab+tirzepatide in obesity) expected 2Q 2025; IND for SRK-439 in 3Q 2025.","COO/CFO Ted Myles departing; search for new CFO; Lisa Wyman appointed CTQO."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177026,"accession_number":"0001104659-25-007028","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Scholar Rock appoints Lisa Wyman as CTQO; COO role eliminated, CFO search begins","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Wyman appointed Chief Technical & Quality Officer effective Jan 27, 2025, reporting to CEO.","Ted Myles, COO & CFO, to remain through Mar 15, 2025, then serve as Senior Advisor until Sep 15, 2025.","Myles receives 9 months base salary, 2024 bonus, prorated $202,400, and 9 months health benefits.","Company expects first drug approval and commercial launch of apitegromab in 2025.","Wyman previously led technical operations at Acceleron, which was sold to Merck for over $11B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177025,"accession_number":"0001558370-25-000184","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scholar Rock furnishes presentation at J.P. Morgan conference; no specific updates visible in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exhibit 99.1 presentation used at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.","Filing text contains no financial or clinical data from the presentation; only form metadata is provided.","No new guidance, trial results, or business developments are disclosed in the 8-K body.","Investor must refer to the presentation itself for any material content, but it is not included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177024,"accession_number":"0001558370-25-000156","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Scholar Rock files corporate slide presentation; no material updates in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated corporate slide deck as Exhibit 99.1 on January 13, 2025.","No financial results, guidance, or specific pipeline events disclosed in the 8-K body.","Investors must review the actual presentation for any strategic or program updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193804,"accession_number":"0001558370-24-015149","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Scholar Rock Phase 3 SAPPHIRE trial meets primary endpoint; Q3 net loss $64.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 SAPPHIRE achieved primary endpoint: apitegromab 1.8-point HFMSE improvement (p=0.0192) vs placebo.","Plans to submit BLA and MAA for apitegromab in SMA in Q1 2025.","Phase 2 EMBRAZE trial (apitegromab + GLP-1 for obesity) fully enrolled; data expected Q2 2025.","Completed upsized $345M public offering; proforma cash $463.5M extends runway into Q4 2026.","Q3 2024 net loss $64.5M ($0.66/share) vs $42.4M ($0.53/share) in Q3 2023; no revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193803,"accession_number":"0001104659-24-107447","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Scholar Rock prices $300M upsized public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$300M; 10,265,488 shares at $28.25/share and 353,983 pre-funded warrants at $28.2499 each.","Underwriters granted 30-day option to purchase up to 1,592,920 additional shares (15% of offering).","Net proceeds ~$282.3M after underwriting discounts and expenses; expected to fund operations into Q4 2026.","Proceeds to support apitegromab commercialization, clinical programs, platform development, and working capital.","Offering expected to close October 10, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193802,"accession_number":"0001104659-24-106461","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apitegromab meets Phase 3 primary endpoint in SMA; Scholar Rock plans BLA/MAA filing Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: apitegromab improved HFMSE vs placebo (mean diff 1.8 points, p=0.0192) in patients ages 2-12.","30.4% of apitegromab patients had >3 point HFMSE improvement vs 12.5% on placebo.","Benefit observed from first time point at 8 weeks, sustained to 52 weeks.","Safety profile consistent with prior trials; no SAEs related to apitegromab.","Company plans to submit BLA to FDA and MAA to EMA in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210142,"accession_number":"0001558370-24-011465","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Scholar Rock Q2 net loss $0.60/shr; cash $190.5M; Phase 3 SAPPHIRE data on track Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $58.5M ($0.60/shr) vs $37.9M ($0.47/shr) in Q2 2023; no revenue.","Cash $190.5M; expected to fund operations into H2 2025.","Phase 3 SAPPHIRE topline data for apitegromab in SMA expected Q4 2024; commercial launch targeted 2025 if successful.","Phase 2 EMBRAZE (apitegromab + GLP-1 in obesity) now expects topline data Q2 2025; IND for SRK-439 planned in 2025.","Long-term TOPAZ data: 48-month mean HFMSE improvement 5.3 points (2-21 yrs); >90% patient retention."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228382,"accession_number":"0001558370-24-009582","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["3.03","5.07","5.03","9.01"],"status":"ready","headline":"Scholar Rock stockholders approve doubling authorized shares to 300M and officer liability limit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 150M to 300M, effective June 27, 2024.","Amendment limiting officer liability (exculpation) approved by stockholders and effective.","Directors Brudnick, Flier, Vaishnaw elected as Class III directors until 2027.","Ernst & Young ratified as auditor for FY 2024.","Advisory say-on-pay approved; frequency set at 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228381,"accession_number":"0001558370-24-009419","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Scholar Rock presents SRK-439 preclinical data showing lean mass preservation and initiates Phase 2 EMBRAZE trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical DIO mouse study: SRK-439 with semaglutide preserved lean mass (26.4g vs 22.3g at 4 weeks, p<0.001) and increased relative lean mass (65.8%) after semaglutide withdrawal vs control (57.1%).","SRK-439 attenuated fat mass rebound after semaglutide withdrawal: relative fat mass 18.0% vs 28.7% (p<0.01) and reduced inguinal and epididymal adipose weights.","First participants dosed in Phase 2 EMBRAZE proof-of-concept trial of apitegromab in obesity patients on GLP-1 RA background therapy to assess lean muscle preservation.","Data presented at ADA 84th Scientific Sessions on June 23, 2024, supporting SRK-439's potential for healthier weight management and long-term metabolic benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228380,"accession_number":"0001558370-24-008865","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Scholar Rock reports positive SRK-181 Phase 1 data across multiple tumors; ccRCC ORR 23.3%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SRK-181 + pembrolizumab showed ORR 23.3% in ccRCC, 27.3% in melanoma, 18.2% in HNSCC, 9.1% in UC; no NSCLC response.","Safety manageable: no Grade 5 AEs; most common AEs were rash, pruritus, fatigue; one Grade 4 dermatitis exfoliative.","Biomarker analysis in ccRCC: baseline CD8+ infiltration doubled ORR to 40%; elevated Treg levels raised ORR to 50%.","Company plans end of Phase 1 meeting with FDA and evaluating partnership opportunities for SRK-181."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228379,"accession_number":"0001558370-24-008556","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Scholar Rock initiates Phase 2 EMBRAZE obesity trial; SRK-439 preclinical data shows superiority over anti-ActRII","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 EMBRAZE proof-of-concept trial initiated for apitegromab in obesity, targeting 100 subjects on GLP-1 RA; primary data expected mid-2025.","Preclinical head-to-head: SRK-439 at 1 mg/kg preserved lean mass equivalent to anti-ActRII at 20 mg/kg; all doses showed superiority.","Loan Amendment No. 4 extends interest-only period to May 2025, modifies milestones for $25M additional tranche available through Dec 2024.","SRK-439 attenuated lean mass loss to 4.2% at 10 mg/kg vs. 14.1% with IgG control + semaglutide in DIO mice.","Company hosts Investor Day; anticipates IND filing for SRK-439 in 2025 after EMBRAZE results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228378,"accession_number":"0001558370-24-008057","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Scholar Rock extends Cambridge HQ lease by ~2 years; base rent ~$6.2M/yr","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease amendment extends term ~2 years starting Aug 19, 2025 (First Extension Term).","Base rent set at ~$120/sq ft, totaling approx. $6.2M per year.","Option to extend lease by an additional 5 years at prevailing market rent after First Extension Term.","Premises remain 51,408 sq ft at 301 Binney St, Cambridge, MA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228377,"accession_number":"0001558370-24-006906","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Scholar Rock Q1 net loss $56.9M ($0.59/shr); Phase 3 SMA data on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $56.9M ($0.59/shr) vs $39.4M ($0.49) Q1 2023; no revenue; R&D up 45% to $43.1M.","Cash $238M as of March 31, 2024; expected to fund operations into 2H 2025.","Phase 3 SAPPHIRE top-line data for apitegromab in SMA on track for Q4 2024; potential commercial launch in 2025 if successful.","Initiating Phase 2 proof-of-concept trial of apitegromab + GLP-1 RA in obesity in June 2024; data expected mid-2025.","SRK-181 data selected for oral presentation at ASCO 2024; SRK-439 preclinical data at ADA 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247093,"accession_number":"0001104659-24-035865","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Scholar Rock reports FY2023 net loss of $165.8M; cash $280M; SAPPHIRE data expected 4Q 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $165.8M ($1.99/share) vs $134.5M ($2.26/share) in FY2022; no revenue vs $33.2M prior year.","R&D spend $121.9M, G&A $49.4M; cash $280M expected to fund operations into 2H 2025.","Phase 3 SAPPHIRE trial (apitegromab in SMA) topline data on track for 4Q 2024; potential launch 2025 if approved.","FDA cleared IND for Phase 2 obesity trial of apitegromab + GLP-1 RA; start mid-2024, data mid-2025.","Appointed Katie Peng to board; promoted Mo Qatanani to CSO in Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247092,"accession_number":"0001104659-24-024369","cik":1727196,"company_name":"Scholar Rock Holding Corp","ticker":"SRRK","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Scholar Rock adds Katie Peng to Board, promotes Mo Qatanani to CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Katie Peng appointed to Board effective Feb 15, 2024; Class II director until 2026 annual meeting.","Amir Nashat will not stand for reelection at 2024 annual meeting; stays on Board and Audit Committee until then.","Peng brings commercial expertise in neurology and rare diseases, including launch of Evrysdi for SMA.","Mo Qatanani promoted to Chief Scientific Officer; leads research and preclinical cardiometabolic program SRK-439.","Company preparing for potential launch of apitegromab for SMA in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5957864924.790679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}